RESUMEN
Three-dimensional QSAR studies for N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones were conducted using TSAR 3.3. The in vitro activities (MICs) of the compounds against Staphylococcus aureus ATCC 25923 exhibited a strong correlation with the prediction made by the model developed in the present study.
Asunto(s)
Antibacterianos/farmacología , Oxazolidinonas/química , Oxazolidinonas/farmacología , Piperazinas/química , Piperazinas/farmacología , Staphylococcus aureus/efectos de los fármacos , Antibacterianos/química , Pruebas de Sensibilidad Microbiana , Relación Estructura-Actividad CuantitativaRESUMEN
Insulin resistance is the major cause in Non Insulin Dependent Diabetes Mellitus (NIDDM). In this review insulin production from beta-cells and action of insulin is briefly described. Any intervention either in the production or action of insulin has been the leading cause of NIDDM. Therapeutic intervention to deal with the defective action of insulin at various receptor or target tissues has been outlined. Structure-activity relationship of a large number of thiazolidinediones, oxazolidinediones, isoxazolidinediones, biguanides, tetrazole derivatives, pyrazoles and pyrazolones, oxathiadiazole oxide, hydroxyurea and carboxylic acid derivatives have been described. The probable mechanism of action of these novel compounds through Peroxisome Proliferator-Activated Receptors that ameliorate the insulin resistance, has been described. Finally the clinical candidates at various stages of clinical evaluation have been compiled.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/química , Hipoglucemiantes/uso terapéutico , Animales , Ensayos Clínicos como Asunto/estadística & datos numéricos , Diabetes Mellitus Tipo 2/metabolismo , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/estadística & datos numéricos , Humanos , Hipoglucemiantes/farmacología , Insulina/biosíntesis , Insulina/genética , Insulina/metabolismo , Resistencia a la Insulina/fisiología , Masculino , Estructura Molecular , Receptores Activados del Proliferador del Peroxisoma/agonistas , Receptores Activados del Proliferador del Peroxisoma/antagonistas & inhibidores , Receptores Activados del Proliferador del Peroxisoma/metabolismo , Relación Estructura-ActividadRESUMEN
We report here the synthesis of a series of 5-[4-[2-[substituted phthalazinones-2(or 4)yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and 5-[4-[2-[2,3-benzoxazine-4-one-2-yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and their plasma glucose and plasma triglyceride lowering activity in db/db mice. In vitro PPARgamma transactivation assay was performed in HEK 293T cells. In vitro and in vivo pharmacological studies showed that the phthalazinone analogue has better activity. PHT46 (compound 5a), the best compound in this series, showed better in vitro PPARgamma transactivation potential than troglitazone and pioglitazone. In insulin resistant db/db mice, PHT46 showed better plasma glucose and triglyceride lowering activity than the standard drugs. Pharmacokinetic study in Wistar rats showed good systemic exposure of PHT46. Subchronic toxicity study in Wistar rats did not show any treatment-related adverse effect.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/síntesis química , Hipoglucemiantes/farmacología , Hipolipemiantes/síntesis química , Hipolipemiantes/farmacología , Oxazinas/farmacología , Ftalazinas/farmacología , Receptores Citoplasmáticos y Nucleares/efectos de los fármacos , Tiazolidinedionas , Factores de Transcripción/efectos de los fármacos , Triglicéridos/antagonistas & inhibidores , Animales , Línea Celular/efectos de los fármacos , Cromanos/farmacología , Modelos Animales de Enfermedad , Femenino , Humanos , Hipoglucemiantes/uso terapéutico , Hipolipemiantes/uso terapéutico , Masculino , Ratones , Ratones Endogámicos C57BL , Oxazinas/química , Ftalazinas/química , Pioglitazona , Ratas , Ratas Wistar , Relación Estructura-Actividad , Tiazoles/química , Tiazoles/farmacología , Triglicéridos/sangre , TroglitazonaRESUMEN
(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid. Compound 6 showed interesting dual activation of PPAR alpha and PPAR gamma. In insulin resistant db/db mice, 6 showed better reduction of plasma glucose and triglyceride levels as compared to rosiglitazone. Compound 6 has also shown good oral bioavailability and impressive pharmacokinetic characteristics. Our study indicates that 6 has great potential as a drug for diabetes and dyslipidemia.
Asunto(s)
Glucemia/análisis , Hipoglucemiantes/síntesis química , Oxazinas/síntesis química , Fenilpropionatos/síntesis química , Receptores Citoplasmáticos y Nucleares/agonistas , Factores de Transcripción/agonistas , Triglicéridos/sangre , Animales , Disponibilidad Biológica , Complicaciones de la Diabetes , Diabetes Mellitus/tratamiento farmacológico , Hiperlipidemias/complicaciones , Hiperlipidemias/tratamiento farmacológico , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Resistencia a la Insulina , Ratones , Oxazinas/farmacocinética , Oxazinas/farmacología , Fenilpropionatos/farmacocinética , Fenilpropionatos/farmacología , Ratas , Ratas Wistar , EstereoisomerismoRESUMEN
Euglycemic and hypolipidemic activities of a novel indole analogue of thiazolidinedione, DRF 2189 (CAS 172647-53-9), have been evaluated in different animal models. Compared to troglitazone (CAS 97322-87-7), DRF 2189 exhibited interesting plasma glucose and triglyceride lowering activity in genetically diabetic and obese db/db mice. It also produced a significant reduction in plasma glucose, triglyceride, total cholesterol levels and improvement in oral glucose tolerance in another genetic mouse model, the ob/ob mice. In high-fat diet fed Sprague-Dawley rats, DRF 2189 treatment showed improvement in plasma lipid parameters. Like other thiazolidinediones, this compound also possesses peroxisome proliferator activated receptor gamma (PPAR gamma) transactivation potential. In anaesthetized rat experiment, DRF 2189 produced a transient fall in blood pressure without any change in the ECG pattern. It showed non-specific smooth muscle relaxant activity against acetylcholine, histamine and potassium chloride induced contractions in isolated guinea pig ileum. A twenty-eight-day toxicity study in Wistar rats did not show any signs of treatment related adverse effects. The overall antidiabetic and hypolipidemic activities of DRF 2189 are comparable with rosiglitazone (CAS 155141-29-0) and superior to troglitazone. In conclusion, results from these preclinical studies indicate that DRF 2189, a novel thiazolidinedione, has a marked potential for the management of type-2 diabetes.
Asunto(s)
Hipoglucemiantes/farmacología , Hipolipemiantes/farmacología , Indoles/farmacología , Tiazoles/farmacología , Tiazolidinedionas , Animales , Presión Sanguínea/efectos de los fármacos , Grasas de la Dieta/farmacología , Cobayas , Hipoglucemiantes/toxicidad , Hipolipemiantes/toxicidad , Íleon/efectos de los fármacos , Técnicas In Vitro , Indoles/toxicidad , Lípidos/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Músculo Liso/efectos de los fármacos , Plásmidos/genética , Ratas , Ratas Sprague-Dawley , Receptores Citoplasmáticos y Nucleares/genética , Receptores Citoplasmáticos y Nucleares/metabolismo , Tiazoles/toxicidad , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Activación Transcripcional/genética , Transfección/genéticaRESUMEN
Several thiazolidinediones having chroman moieties were synthesized and evaluated for their euglycemic and hypolipidemic activities. Some of the analogues having an aminoalkyl group as a linker between the chroman ring and 4-[5-(2,4-dioxo-1, 3-thiazolidinyl)methyl]phenoxy moiety seem to be better than troglitazone. In vitro transactivation assays of PPARgamma have been carried out with these glitazones to understand their molecular mechanism. For the first time we have found that some of the unsaturated thiazolidinediones are superior to their saturated counterpart in the in vivo assay. A more potent thiazolidinedione analogue than troglitazone is reported. Pharmacokinetic studies have shown that protection of the OH group in the chroman moiety leads to a decrease in metabolism, thereby resulting in a superior pharmacological profile.
Asunto(s)
Cromanos/síntesis química , Hipoglucemiantes/síntesis química , Hipolipemiantes/síntesis química , Tiazoles/síntesis química , Animales , Glucemia/metabolismo , Cromanos/química , Cromanos/farmacocinética , Cromanos/farmacología , Femenino , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Hipolipemiantes/química , Hipolipemiantes/farmacocinética , Hipolipemiantes/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratas , Ratas Wistar , Receptores Citoplasmáticos y Nucleares/agonistas , Relación Estructura-Actividad , Tiazoles/química , Tiazoles/farmacocinética , Tiazoles/farmacología , Factores de Transcripción/agonistas , Triglicéridos/sangreRESUMEN
A series of substituted pyridyl- and quinolinyl-containing 2, 4-thiazolidinediones having interesting cyclic amine as a linker have been synthesized. Both unsaturated thiazolidinediones 5 and saturated thiazolidinediones 6 and their various salts were evaluated in db/db mice for euglycemic and hypolipidemic effects and compared with BRL compound 11 and BRL-49653, respectively. Some of the potent compounds were converted to various salts in order to obtain improved activities. Among all the salts evaluated, the maleate salt of unsaturated TZD 5a was found to be a very potent euglycemic and hypolipidemic compound. Some of the more interesting compounds have also been evaluated in ob/ob mice and compared with rosiglitazone (maleate salt of BRL-49653). Oral glucose tolerance tests were performed in both db/db and ob/ob mice. Pharmacokinetic studies of 5a maleate are also reported. Receptor binding studies of PPARgamma by 5a/5a maleate did not show any significant transactivation of PPARalpha or PPARgamma.
Asunto(s)
Hipoglucemiantes/síntesis química , Hipolipemiantes/síntesis química , Piridinas/síntesis química , Quinolinas/síntesis química , Tiazoles/síntesis química , Tiazolidinedionas , Animales , Prueba de Tolerancia a la Glucosa , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Hipolipemiantes/química , Hipolipemiantes/farmacocinética , Hipolipemiantes/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Piridinas/química , Piridinas/farmacocinética , Piridinas/farmacología , Quinolinas/química , Quinolinas/farmacocinética , Quinolinas/farmacología , Ratas , Ratas Wistar , Relación Estructura-Actividad , Tiazoles/química , Tiazoles/farmacocinética , Tiazoles/farmacologíaRESUMEN
Several thiazolidinedione derivatives having 5-hydroxy-2,3-dihydro-2, 2,4,6,7-pentamethylbenzofuran moieties and their 5-benzyloxy derivatives and 5-hydroxy-2,4,6,7-tetramethylbenzofuran moieties were synthesized and evaluated in db/db mice. Insertion of an N-Me group into the linker between thiazolidinedione and substituted benzofuran pharmacophores showed considerable improvement in their euglycemic activity. Further improvement has been observed when a pyrrolidine moiety is introduced in the structure to give 5-[4-[N-[3(R/S)-5-benzyloxy-2,3-dihydro-2,2,4,6, 7-pentamethylbenzofuran-3-ylmethyl]-(2S)-pyrrolidin-2- ylmethoxy]pheny lene]thiazolidine-2,4-dione (21a). At a 100 mg/kg/day dose of the maleate salt, compound 21a reduced the plasma glucose and triglyceride to the level of lean littermate, i.e. 8 +/- 1 mM, and is the most potent and efficacious compound reported in this series.
Asunto(s)
Hipoglucemiantes/síntesis química , Hipolipemiantes/síntesis química , Pirrolidinas/síntesis química , Tiazoles/síntesis química , Animales , Glucemia/metabolismo , Femenino , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Hipolipemiantes/química , Hipolipemiantes/farmacocinética , Hipolipemiantes/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Pirrolidinas/química , Pirrolidinas/farmacocinética , Pirrolidinas/farmacología , Ratas , Ratas Wistar , Receptores Citoplasmáticos y Nucleares/agonistas , Relación Estructura-Actividad , Tiazoles/química , Tiazoles/farmacocinética , Tiazoles/farmacología , Factores de Transcripción/agonistas , Triglicéridos/sangreRESUMEN
The pharmacokinetics of the new insulin sensitizing agent, DRF-2189 ([5-[4-[2-(1-indolyl) ethoxy]phenyl]methyl]thiazolidine-2,4-dione, CAS 172647-53-9) were studied in male Wistar rats following oral doses of 1, 3 and 10 mg/kg as suspension in 0.25% carboxymethylcellulose. Drug was extracted from plasma samples using a solvent mixture containing ethylacetate and dichloromethane (3:2) and analyzed by high-performance liquid chromatography with fluorescence detection. DRF-2189 was absorbed slowly, attaining maximum levels at 2-3 h, and was eliminated with a half-life (t1/2) of about 3 h. The Cmax and AUC(0-infinity) increased linearly (r2 = 0.99) with the dose, while the elimination half-life (t1/2) was independent of the dose. An intravenous pharmacokinetic study of DRF-2189 was carried out in Wistar rats at a dose of 3.0 mg/kg. The pharmacokinetic parameters AUC(0-infinity), t1/2, plasma clearance (Cl) and volume of distribution (Vd) were found to be 49.52 micrograms x h/ml, 2.99 h, 16.31 ml/h and 45.11 ml. respectively. Oral bioavailability (f) of DRF-2189 in Wistar rats was 44%. Based on pharmacokinetic studies, DRF-2189 is a good choice for further development.
Asunto(s)
Hipoglucemiantes/farmacocinética , Indoles/farmacocinética , Insulina/agonistas , Tiazoles/farmacocinética , Tiazolidinedionas , Animales , Área Bajo la Curva , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Semivida , Hipoglucemiantes/administración & dosificación , Indicadores y Reactivos , Indoles/administración & dosificación , Inyecciones Intravenosas , Masculino , Ratas , Ratas Wistar , Tiazoles/administración & dosificaciónRESUMEN
A series of [[(heterocyclyl)ethoxy]benzyl]-2,4-thiazolidinediones have been synthesized by the condensation of corresponding aldehyde 1 and 2,4-thiazolidinedione followed by hydrogenation. Both unsaturated thiazolidinedione 2 and its saturated counterpart 3 have shown antihyperglycemic activity. Many of these compounds have shown superior euglycemic and hypolipidemic activity compared to troglitazone (CS 045). The indole analogue DRF-2189 (3g) was found to be a very potent insulin sensitizer, comparable to BRL-49653 in genetically obese C57BL/6J-ob/ob and 57BL/KsJ-db/db mice. Pharmacokinetic and tissue distribution studies conducted on BRL-49653 and DRF-2189 (3g) indicate that these drugs are well-distributed in target tissues. On the basis of euglycemic activity as well as enhanced selectivity against reduction of triglycerides in plasma, DRF-2189 (3g) has been selected for further evaluation.
Asunto(s)
Hipoglucemiantes , Hipolipemiantes , Indoles , Tiazoles , Tiazolidinedionas , Animales , Glucemia/metabolismo , Evaluación Preclínica de Medicamentos , Hipoglucemiantes/síntesis química , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Hipolipemiantes/síntesis química , Hipolipemiantes/química , Hipolipemiantes/farmacocinética , Hipolipemiantes/farmacología , Indoles/síntesis química , Indoles/química , Indoles/farmacocinética , Indoles/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratas , Ratas Wistar , Rosiglitazona , Relación Estructura-Actividad , Tiazoles/síntesis química , Tiazoles/química , Tiazoles/farmacocinética , Tiazoles/farmacología , Distribución Tisular , Triglicéridos/sangreRESUMEN
Several 7-(3R,4R-N,N'-dialkyl diaminopyrrolidinyl)-substituted quinolones were synthesized and evaluated for antibacterial activities. 5-Amino-7-(3R,4R-N,N'-dimethyldiamino-6,8-difluoro-1,4-dihydro-1-c yclopropyl -4-oxoquinoline-3-carboxylic acid was found to have potent antibacterial activity against gram +ve organisms.
Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Quinolonas/farmacología , Antibacterianos/química , Pruebas de Sensibilidad Microbiana , Quinolonas/química , Especificidad de la Especie , Relación Estructura-ActividadRESUMEN
Several thiazolidinediones having antioxidant moities in their structural motif have been synthesised and evaluated for their euglycemic and hypolipidemic activities. A few of them have been found to be superior to troglitazone.